Headlines about Quest Diagnostics (NYSE:DGX) have been trending positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Quest Diagnostics earned a media sentiment score of 0.26 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 46.5831523140634 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Quest Diagnostics (NYSE DGX) traded up $1.44 during trading hours on Friday, hitting $104.53. The stock had a trading volume of 771,191 shares, compared to its average volume of 1,070,000. The firm has a market cap of $14,250.00, a PE ratio of 16.67, a P/E/G ratio of 1.88 and a beta of 0.67. Quest Diagnostics has a twelve month low of $90.10 and a twelve month high of $112.96. The company has a current ratio of 1.24, a quick ratio of 1.15 and a debt-to-equity ratio of 0.76.
Quest Diagnostics (NYSE:DGX) last released its quarterly earnings data on Thursday, February 1st. The medical research company reported $1.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.37 by $0.03. The business had revenue of $1.94 billion during the quarter, compared to analysts’ expectations of $1.93 billion. Quest Diagnostics had a return on equity of 15.41% and a net margin of 10.00%. The business’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.31 EPS. research analysts forecast that Quest Diagnostics will post 6.59 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 18th. Stockholders of record on Wednesday, April 4th will be given a dividend of $0.50 per share. This is a boost from Quest Diagnostics’s previous quarterly dividend of $0.45. This represents a $2.00 annualized dividend and a dividend yield of 1.91%. The ex-dividend date is Tuesday, April 3rd. Quest Diagnostics’s dividend payout ratio is currently 28.71%.
A number of research firms have commented on DGX. Credit Suisse Group upgraded Quest Diagnostics from a “neutral” rating to an “outperform” rating and set a $107.00 target price on the stock in a research report on Tuesday, February 13th. Zacks Investment Research upgraded Quest Diagnostics from a “hold” rating to a “buy” rating and set a $115.00 target price on the stock in a research report on Tuesday, February 6th. Piper Jaffray Companies restated a “hold” rating and issued a $110.00 target price on shares of Quest Diagnostics in a research report on Thursday, February 1st. Goldman Sachs Group began coverage on Quest Diagnostics in a research report on Monday, January 29th. They issued a “buy” rating and a $117.00 target price on the stock. Finally, Mizuho set a $113.00 target price on Quest Diagnostics and gave the company a “buy” rating in a research report on Wednesday, January 24th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and nine have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $107.40.
In related news, EVP J. E. Davis sold 63,880 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $98.68, for a total value of $6,303,678.40. Following the completion of the sale, the executive vice president now directly owns 101,423 shares of the company’s stock, valued at approximately $10,008,421.64. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Catherine T. Doherty sold 21,294 shares of the company’s stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $104.00, for a total value of $2,214,576.00. Following the completion of the sale, the senior vice president now directly owns 90,709 shares of the company’s stock, valued at $9,433,736. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 192,014 shares of company stock valued at $19,950,134. Insiders own 1.75% of the company’s stock.
Quest Diagnostics Company Profile
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.